BUSINESS

• Santen, RIKEN, FBRI Sign Drug Discovery Deal for Retinal Disease
  October 7, 2016

• Teikoku Seiyaku, Mitsubishi Tanabe Hook Up on Sales of Anti-Allergy Agents
  October 6, 2016

• GHIT Fund to Invest 1.1 Billion Yen in Development of Neglected Disease Drugs
  October 6, 2016

• Eurofarma Gets Latin American Rights to Eisai’s Cancer Candidate Farletuzumab
  October 5, 2016

• Daiichi Sankyo, AgonOx Ink Immuno-Oncology Research Collaboration
  October 5, 2016

• Marc van der Heijden to Lead Allergan Japan
  October 4, 2016

• Daiichi Sankyo Launches Large-Scale Research in Elderly NVAF Patients
  October 4, 2016

• Constipation Drug Delivers Positive PIII Data in Japan: EA Pharma, Mochida
  October 4, 2016

• Mitsubishi Tanabe Looks to Double Late-Stage Pipelines; Faster Decisions Hold Key in Curbing Costs
  October 3, 2016

• Data Out to Support Long-Term Use of Entyvio: Takeda
  October 3, 2016

• Eisai to Kick Off Global PIII for Lenvatinib as First-Line RCC Therapy
  October 3, 2016

• Mochida to Solely Distribute Janssen’s Pain Drug Tramcet from January
  October 3, 2016

• Teva Pharma Japan Renamed “Teva Takeda Pharma”
  October 3, 2016

• Takecab Most Heavily Promoted Drug in August: Anterio
  October 3, 2016

• Suzuken’s Harvoni Sales Sag 70% from Peak, Wholesaler Earnings Certain to Take Hit
  September 30, 2016

• Daiichi Sankyo, Zymeworks Seal Immuno-Oncology Cross-Licensing Pact
  September 30, 2016

• Chugai Licenses Atopic Dermatitis Hopeful to Maruho in Japan, Retains Rights for Hemodialysis Pruritus
  September 29, 2016

• Maruho Gets Rights to Astellas’ JAK Inhibitor for Skin Diseases
  September 29, 2016

• Pruritus Drug Remitch Filed for Use in Peritoneal Dialysis Patients
  September 29, 2016

• Tokyo Startup’s Osteoarthritis Drug Hopeful on Tap for PIb Launch by Year-End
  September 28, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 466
• 467
• 468
• 469
• 470
• 471
• 472
• 473
• 474
• …
• Next ›
• 最終 »